Inhibition of DPP4 activity in humans establishes its in vivo role in CXCL10 post‐translational modification: prospective placebo‐controlled clinical studies

• Published in: EMBO molecular medicine Vol. 8; no. 6; pp. 679 - 683
• Main Authors: Decalf, Jérémie, Tarbell, Kristin V, Casrouge, Armanda, Price, Jeffrey D, Linder, Grace, Mottez, Estelle, Sultanik, Philippe, Mallet, Vincent, Pol, Stanislas, Duffy, Darragh, Albert, Matthew L
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.06.2016; Wiley Open Access; John Wiley and Sons Inc; Springer Nature
• Subjects: Chemokine CXCL10 - blood; Chemokine CXCL10 - metabolism; chemokines; clinical study; CXCL10; Dipeptidyl Peptidase 4 - metabolism; Dipeptidyl-Peptidase IV Inhibitors - administration & dosage; DPP4; EMBO23; EMBO28; EMBO31; Healthy Volunteers; Hepatitis C, Chronic - pathology; Humans; Immunology; Life Sciences; Placebos - administration & dosage; post‐translational modifications; Prospective Studies; Protein Processing, Post-Translational; Proteolysis; Sitagliptin Phosphate - administration & dosage; clinical study; DPP4; post‐translational modifications; CXCL10; chemokines

Biochemical experiments, animal models, and observational studies in humans all support a role of dipeptidyl peptidase 4 (DPP4) in the N‐terminal truncation of CXCL10, which results in the generation of an antagonist form of the chemokine that limits T‐cell and NK cell migration. Motivated by the ab...